The latest iteration of a House bill reauthorizing the FDA's user fee program says the FDA "may" expedite review of certain competitive generic-drug applications upon request. The previous version of the bill said "shall."
House user fee bill softens generic-drug competition language
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.